Author: Warner, Bryce M.; Santry, Lisa A.; Leacy, Alexander; Chan, Mable; Pham, Phuc H.; Vendramelli, Robert; Pei, Yanlong; Tailor, Nikesh; Valcourt, Emelissa; Leung, Anders; He, Shihua; Griffin, Bryan D.; Audet, Jonathan; Willman, Marnie; Tierney, Kevin; Albietz, Alixandra; Frost, Kathy L.; Yates, Jacob G.E.; Mould, Robert C.; Chan, Lily; Mehrani, Yeganeh; Knapp, Jason P.; Minott, Jessica A.; Banadyga, Logan; Safronetz, David; Wood, Heidi; Booth, Stephanie; Major, Pierre P.; Bridle, Byram W.; Susta, Leonardo; Kobasa, Darwyn; Wootton, Sarah K.
Title: Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease Cord-id: v6i2afp5 Document date: 2021_10_6
ID: v6i2afp5
Snippet: The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SAR
Document: The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs, but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19.
Search related documents:
Co phrase search for related documents- acute infection and additional gene: 1, 2
- acute infection and additional information: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute infection and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and long term outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and lung parenchyma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute infection and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute time point and additional information: 1
- acute virus and additional information: 1, 2
- acute virus and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute virus and lung parenchyma: 1, 2, 3, 4
- acute virus and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- additional gene and live vaccine: 1
- additional information and live vaccine: 1, 2, 3
- additional information and long term outcome: 1
- additional information and lung parenchyma: 1, 2
- additional information and lung pathology: 1
- live vaccine and long term outcome: 1
- live vaccine and lung pathology: 1, 2, 3, 4, 5
- long term outcome and lung parenchyma: 1
Co phrase search for related documents, hyperlinks ordered by date